Video

Dr. Johnson on the Effect of the IPSOS Trial on Treatment in Platinum-Ineligible NSCLC

Melissa L. Johnson, MD, discusses the paradigm-shifting results of the phase 3 IPSOS trial of atezolizumab in patients with metastatic non­–small cell lung cancer.

Melissa L. Johnson, MD, program director of Lung Cancer Research, lead of the Solid Tumor Immune Effector Cellular Therapy Program, Sarah Cannon Research Institute, discusses the paradigm-shifting results of the phase 3 IPSOS trial (NCT03191786) of atezolizumab (Tecentriq) in patients with metastatic non­–small cell lung cancer (NSCLC).

Historically, clinicians have attempted to conclusively demonstrate the superiority of platinum-based doublet therapy to single-agent chemotherapy and establish this regimen as the standard of care in all patients with NSCLC irrespective of age and performance status, Johnson states.

The IPSOS trial identified an unmet need for patients with NSCLC who are not eligible to receive platinum-based combination regimens due to pre-existing or treatment-related comorbidities, Johnson continues. The trial aimed to address the lack of treatment alternatives to platinum therapy by evaluating the PD-L1 inhibitor atezolizumab (Tecentriq) in treatment-naïve patients with locally advanced, recurrent, or metastatic NSCLC.

Patients were randomly assigned to single-agent atezolizumab vs treatment with standard vinorelbine or gemcitabine. Results demonstrated an improvement in overall survival in patients receiving atezolizumab, suggesting that anti–PD-L1 immunotherapies are preferable to platinum-based doublet chemotherapy in this patient population, Johnson concludes.

Related Videos
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.